Charting New Territory With a Novel WHO Provisional Category: A Case Study of a Low-Grade Oncocytic Tumor (LOT) in the Kidney

TL;DR

This paper presents a case study of a rare kidney tumor, LOT, highlighting its unique features and favorable prognosis to guide better patient management.

Contribution

The paper contributes a detailed case study of a newly classified WHO kidney tumor, emphasizing its distinct clinical and pathological characteristics.

Findings

LOT is a distinct oncocytic tumor with CK7 expression and no CD117 expression.

LOT typically presents as a small, solitary lesion with a low stage and indolent clinical course.

The case study shows a favorable one-year follow-up, supporting conservative management strategies.

Abstract

A low-grade oncocytic tumor of the kidney (LOT) is a distinctive entity categorized under the 2022 World Health Organization (WHO) classification as "Other oncocytic tumors of the kidney.” It represents a unique subset of oncocytic tumors, distinct from oncocytoma and chromophobe renal cell carcinoma. Characterized by bland oncocytic cells that diffusely express CK7 and lack CD117 expression, LOT typically manifests as a solitary, small lesion with a low stage. Available data suggest that LOT follows an indolent clinical course. Herein, we present a case of LOT in a 64-year-old male with a favorable course at a one-year follow-up. Understanding the clinical, morphological, and immunophenotypic features of LOT is paramount for accurate identification and characterization. This knowledge facilitates more conservative surgical and clinical management, optimizing patient care and outcomes.

Figures